Enfusion price target raised to $9 from $8 at BofA

BofA analyst Koji Ikeda raised the firm’s price target on Enfusion to $9 from $8 and keeps an Underperform rating on the shares. Enfusion’s Q4 results were “good,” but sustained outperformance is “uncertain” and next week’s investor day is “key,” the analyst tells investors in a post-earnings note.